Trial Profile
Activity of Abiraterone Acetate in the management of Cushing's syndrome in patients with adrenocortical carcinoma (ABACUS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Mitotane (Primary) ; Antineoplastics
- Indications Adrenocortical carcinoma; Cushing syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms ABACUS
- 29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database.
- 11 May 2017 New trial record